|
| Evidence summary and evaluation of randomized controlled trials on the treatment of hyperlipidemia with Chinese patent medicines |
| Hits 53 Download times 4 Received:December 20, 2024 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2025.04.08 |
| Key Words
Chinese patent medicine;hyperlipidemia;randomized controlled trial;evidence-based medicine;traditional Chinese medicine |
| Author Name | Affiliation | E-mail | | MA Yucong | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | HU Haiyin | Haihe Laboratory of Modern Chinese Medicine, Tianjin 301617, China | | | PENG Dehui | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | WANG Danlei | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | SHI Menglong | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | LIU Xiaoxuan | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | WANG Hui | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
Haihe Laboratory of Modern Chinese Medicine, Tianjin 301617, China | | | ZHANG Junhua | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
Haihe Laboratory of Modern Chinese Medicine, Tianjin 301617, China | | | JI Zhaochen | Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
Haihe Laboratory of Modern Chinese Medicine, Tianjin 301617, China | robin_johnson@foxmail.com |
|
| Abstract
|
| [Objective] This study comprehensively collects and analyzes the clinical evidence on the treatment of hyperlipidemia with proprietary Chinese medicines，aiming to provide references for the rational use of medicines in the clinic，the optimization of therapeutic regimens，and the development of follow-up studies. [Methods] The RCT of DFU treated with Chinese patent medicine was obtained and analyzed using the AI-clinical evidence database of Chinese patent medicine（AICED-CPM）. The analysis was supplemented with data from CNKI，Wanfang Database，VIP，SinoMed，PubMed，EMbase，Cochrane Library，and Web of Science. Researchers independently screened the literature and extracted information according to inclusion and exclusion criteria，and assessed the risk of bias using the RoB 2.0. [Resules] A total of 637 studies involving 196 types of drugs（175 oral Chinese patent medicines and 21 traditional Chinese medicine injections） were included，with 65 RCTs having a patient sample size of 200 or more. The most commonly used intervention/control design was Chinese patent medicine vs. Western medicine（165 articles，25.90%）. A total of 197 outcomes were reported，including 26 counting outcomes（903 times） and 171 measuring outcomes（3 000 times）. The quality evaluation showed that the overall quality of RCTs on the treatment of hyperlipidemia with Chinese patent medicines was suboptimal，with significant deficiencies in the reporting of allocation concealment，blinding of participants，and other biases. [Conclusions] A large number of Chinese patent medicines were involved in the included RCTs. Mainly oral drugs，and the outcomes were mainly quantitative outcomes，indicating that traditional Chinese medicine had been extensively explored in the treatment of hyperlipidemia. It is recommended that future studies should refer to the new version of the guideline to set the outcome evaluation indexes；improve the rigor of RCT design，implementation，and reporting；clarify the identification and typing of Chinese medicine，and refine the clinical treatment protocols，to facilitate the translation of the clinical evidence to practice and provide evidence support for the conduct of subsequent studies. |
|
|
|
|
|
|
|
